Cargando…

Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0

Detalles Bibliográficos
Autores principales:	Vairetti, Mariapia, Colucci, Giuseppe, Ferrigno, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319880/ https://www.ncbi.nlm.nih.gov/pubmed/35887242 http://dx.doi.org/10.3390/ijms23147894

Ejemplares similares

Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Drescher, Hannah K., et al.
Publicado: (2019)

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
por: Younossi, Zobair M., et al.
Publicado: (2023)

Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)
por: Wen, Xuerong, et al.
Publicado: (2021)

Therapeutic Effects of microRNAs on Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review and Meta-Analysis
por: Zhu, Yuezhi, et al.
Publicado: (2023)

Sugar-Sweetened Beverages and Artificially Sweetened Beverages Consumption and the Risk of Nonalcoholic Fatty Liver (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Tseng, Tung-Sung, et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research
por: Berardo, Clarissa, et al.
Publicado: (2020)

Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain
por: Romero-Gomez, Manuel, et al.
Publicado: (2020)

Animal Models of Steatosis (NAFLD) and Steatohepatitis (NASH) Exhibit Hepatic Lobe-Specific Gelatinases Activity and Oxidative Stress
por: Palladini, Giuseppina, et al.
Publicado: (2019)

Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database
por: Terai, Shuji, et al.
Publicado: (2021)

Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH)
por: Murphy, William A., et al.
Publicado: (2022)

353. A Comparison Study of Prevalence and Risk Factors for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) by Transient Elastography (TE) in HIV-Infected Patients
por: Choe, Sunny, et al.
Publicado: (2019)

The burden of nonalcoholic steatohepatitis (NASH) in the United States
por: Tapper, Elliot B., et al.
Publicado: (2023)

Associations between serum trace elements and inflammation in two animal models of nonalcoholic fatty liver disease
por: Palladini, Giuseppina, et al.
Publicado: (2020)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Nonalcoholic steatohepatitis (NASH) is associated with cardiac remodeling and dysfunction
por: Simon, Tracey G., et al.
Publicado: (2017)

Exosomal microRNAs and Progression of Nonalcoholic Steatohepatitis (NASH)
por: Qi, Xiaoyan, et al.
Publicado: (2022)

Assessment of Imaging Modalities Against Liver Biopsy in Nonalcoholic Fatty Liver Disease: The Amsterdam NAFLD‐NASH Cohort
por: Troelstra, Marian A., et al.
Publicado: (2021)

The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Cha, Ji-Young, et al.
Publicado: (2018)

Targeting of Secretory Proteins as a Therapeutic Strategy for Treatment of Nonalcoholic Steatohepatitis (NASH)
por: Kim, Kyeongjin, et al.
Publicado: (2020)

Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Lee, Chanbin, et al.
Publicado: (2019)

Omega-3 Polyunsaturated Fatty Acids Prevent Nonalcoholic Steatohepatitis (NASH) and Stimulate Adipogenesis
por: Antraco, Vitor Jacó, et al.
Publicado: (2021)

Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma
por: Kutlu, Ozlem, et al.
Publicado: (2018)

A new method to induce nonalcoholic steatohepatitis (NASH) in mice
por: Savari, Feryal, et al.
Publicado: (2019)

A Novel Animal Model of Nonalcoholic Steatohepatitis (NASH): Hypoxemia Enhances the Development of NASH
por: Takayama, Fusako, et al.
Publicado: (2009)

Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Amjad, Waseem, et al.
Publicado: (2023)

Magnetic resonance‐based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Caussy, Cyrielle, et al.
Publicado: (2020)

Free fatty acid-based low-impedance liver image: a characteristic appearance in nonalcoholic steatohepatitis (NASH)
por: Maruyama, Hitoshi, et al.
Publicado: (2020)

PPAR Alpha as a Metabolic Modulator of the Liver: Role in the Pathogenesis of Nonalcoholic Steatohepatitis (NASH)
por: Todisco, Simona, et al.
Publicado: (2022)

Detailed Molecular Mechanisms Involved in Drug-Induced Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: An Update
por: Di Pasqua, Laura Giuseppina, et al.
Publicado: (2022)

Plasma Pentraxin3 is a Novel Marker for Nonalcoholic Steatohepatitis (NASH)
por: Yoneda, Masato, et al.
Publicado: (2008)

Population Pharmacokinetics of Morphine in Patients With Nonalcoholic Steatohepatitis (NASH) and Healthy Adults
por: Pierre, V, et al.
Publicado: (2017)

Imaging Fibrogenesis in a Diet-Induced Model of Nonalcoholic Steatohepatitis (NASH)
por: Hartimath, S. V., et al.
Publicado: (2019)

Hepatic Molecular Signatures Highlight the Sexual Dimorphism of Nonalcoholic Steatohepatitis (NASH)
por: Vandel, Jimmy, et al.
Publicado: (2020)

The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression
por: Li, Xinzhi, et al.
Publicado: (2021)

The OMICs Window into Nonalcoholic Fatty Liver Disease (NAFLD)
por: Carulli, Lucia, et al.
Publicado: (2019)

Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease
por: Lee, Hye Won, et al.
Publicado: (2016)

Gut microbiota profile in patients with nonalcoholic fatty liver disease and presumed nonalcoholic steatohepatitis
por: Mohammadi, Zahra, et al.
Publicado: (2022)

Can Nutritional Supplements Benefit Patients With Nonalcoholic Steatohepatitis and Nonalcoholic Fatty Liver Disease?
por: Baradeiya, Ahmed M, et al.
Publicado: (2023)

Ablation of the deubiquitinase USP15 ameliorates nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Baek, Jung-Hwan, et al.
Publicado: (2023)

Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis
por: Dongiovanni, Paola, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vkhf0mj7gthf46sdkd0v1lsfif